Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 Dec;63(12):4619–4627. doi: 10.1128/iai.63.12.4619-4627.1995

Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.

J F Torres 1, D M Lyerly 1, J E Hill 1, T P Monath 1
PMCID: PMC173664  PMID: 7591115

Abstract

Clostridium difficile produces toxins that cause inflammation, necrosis, and fluid in the intestine and is the most important cause of nosocomial antibiotic-associated diarrhea and colitis. We evaluated C. difficile antigens as vaccines to protect against systemic and intestinal disease in a hamster model of clindamycin colitis. Formalin-inactivated culture filtrates from a highly toxigenic strain were administered by mucosal routes (intranasal, intragastric, and rectal) with cholera toxin as a mucosal adjuvant. A preparation of culture filtrate and killed whole cells was also tested rectally. The toxoid was also tested parenterally (subcutaneously and intraperitoneally) and by a combination of three intranasal immunizations followed by a combined intranasal-intraperitoneal boost. Serum antibodies against toxins A and B and whole-cell antigen were measured by enzyme-linked immunosorbent assay, neutralization of cytotoxic activity, and bacterial agglutination. The two rectal immunization regimens induced low antibody responses and protected only 20% of hamsters against death and 0% against diarrhea. The intragastric regimen induced high antibody responses but low protection, 40% against death and 0% against diarrhea. Hamsters immunized by the intranasal, intraperitoneal, and subcutaneous routes were 100% protected against death and partially protected (40, 40, and 20%, respectively) against diarrhea. Among the latter groups, intraperitoneally immunized animals had the highest serum anticytotoxic activity and the highest agglutinating antibody responses. Hamsters immunized intranasally and revaccinated intraperitoneally were 100% protected against both death and diarrhea. Protection against death and diarrhea correlated with antibody responses to all antigens tested. The results indicate that optimal protection against C. difficile disease can be achieved with combined parenteral and mucosal immunization.

Full Text

The Full Text of this article is available as a PDF (337.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apter F. M., Michetti P., Winner L. S., 3rd, Mack J. A., Mekalanos J. J., Neutra M. R. Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo. Infect Immun. 1993 Dec;61(12):5279–5285. doi: 10.1128/iai.61.12.5279-5285.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bacon A. E., 3rd, Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. Diagn Microbiol Infect Dis. 1994 Apr;18(4):205–209. doi: 10.1016/0732-8893(94)90021-3. [DOI] [PubMed] [Google Scholar]
  3. Barroso L. A., Wang S. Z., Phelps C. J., Johnson J. L., Wilkins T. D. Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res. 1990 Jul 11;18(13):4004–4004. doi: 10.1093/nar/18.13.4004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bartlett J. G. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis. 1994 May;18 (Suppl 4):S265–S272. doi: 10.1093/clinids/18.supplement_4.s265. [DOI] [PubMed] [Google Scholar]
  5. Bassaris H. P., Lianou P. E., Legakis N. J., Papavassiliou J. T. Interaction between Clostridium difficile and polymorphonuclear leucocytes from the elderly and post-operative cancer patients: phagocytosis and bactericidal function. Med Microbiol Immunol. 1984;173(1):49–55. doi: 10.1007/BF02123569. [DOI] [PubMed] [Google Scholar]
  6. Bender B. S., Bennett R., Laughon B. E., Greenough W. B., 3rd, Gaydos C., Sears S. D., Forman M. S., Bartlett J. G. Is Clostridium difficile endemic in chronic-care facilities? Lancet. 1986 Jul 5;2(8497):11–13. doi: 10.1016/s0140-6736(86)92559-6. [DOI] [PubMed] [Google Scholar]
  7. Corthier G., Muller M. C., Wilkins T. D., Lyerly D., L'Haridon R. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun. 1991 Mar;59(3):1192–1195. doi: 10.1128/iai.59.3.1192-1195.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dailey D. C., Kaiser A., Schloemer R. H. Factors influencing the phagocytosis of Clostridium difficile by human polymorphonuclear leukocytes. Infect Immun. 1987 Jul;55(7):1541–1546. doi: 10.1128/iai.55.7.1541-1546.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dove C. H., Wang S. Z., Price S. B., Phelps C. J., Lyerly D. M., Wilkins T. D., Johnson J. L. Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun. 1990 Feb;58(2):480–488. doi: 10.1128/iai.58.2.480-488.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ehrich M., Van Tassell R. L., Libby J. M., Wilkins T. D. Production of Clostridium difficile antitoxin. Infect Immun. 1980 Jun;28(3):1041–1043. doi: 10.1128/iai.28.3.1041-1043.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fernie D. S., Thomson R. O., Batty I., Walker P. D. Active and passive immunization to protect against antibiotic associated caecitis in hamsters. Dev Biol Stand. 1983;53:325–332. [PubMed] [Google Scholar]
  12. Flegel W. A., Müller F., Däubener W., Fischer H. G., Hadding U., Northoff H. Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infect Immun. 1991 Oct;59(10):3659–3666. doi: 10.1128/iai.59.10.3659-3666.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Forrest B. D., Shearman D. J., LaBrooy J. T. Specific immune response in humans following rectal delivery of live typhoid vaccine. Vaccine. 1990 Jun;8(3):209–212. doi: 10.1016/0264-410x(90)90047-p. [DOI] [PubMed] [Google Scholar]
  14. Haneberg B., Kendall D., Amerongen H. M., Apter F. M., Kraehenbuhl J. P., Neutra M. R. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect Immun. 1994 Jan;62(1):15–23. doi: 10.1128/iai.62.1.15-23.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hecht G., Koutsouris A., Pothoulakis C., LaMont J. T., Madara J. L. Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology. 1992 Feb;102(2):416–423. doi: 10.1016/0016-5085(92)90085-d. [DOI] [PubMed] [Google Scholar]
  16. Hecht G., Pothoulakis C., LaMont J. T., Madara J. L. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest. 1988 Nov;82(5):1516–1524. doi: 10.1172/JCI113760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Holbrook W. P., Duerden B. I., Deacon A. G. The classification of Bacteroides melaninogenicus and related species. J Appl Bacteriol. 1977 Apr;42(2):259–273. doi: 10.1111/j.1365-2672.1977.tb00691.x. [DOI] [PubMed] [Google Scholar]
  18. Johnson S., Gerding D. N., Janoff E. N. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis. 1992 Dec;166(6):1287–1294. doi: 10.1093/infdis/166.6.1287. [DOI] [PubMed] [Google Scholar]
  19. Karjalainen T., Barc M. C., Collignon A., Trollé S., Boureau H., Cotte-Laffitte J., Bourlioux P. Cloning of a genetic determinant from Clostridium difficile involved in adherence to tissue culture cells and mucus. Infect Immun. 1994 Oct;62(10):4347–4355. doi: 10.1128/iai.62.10.4347-4355.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kelly C. P., Pothoulakis C., Orellana J., LaMont J. T. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology. 1992 Jan;102(1):35–40. doi: 10.1016/0016-5085(92)91781-x. [DOI] [PubMed] [Google Scholar]
  21. Ketley J. M., Mitchell T. J., Candy D. C., Burdon D. W., Stephen J. The effects of Clostridium difficile crude toxins and toxin A on ileal and colonic loops in immune and non-immune rabbits. J Med Microbiol. 1987 Aug;24(1):41–52. doi: 10.1099/00222615-24-1-41. [DOI] [PubMed] [Google Scholar]
  22. Kim P. H., Iaconis J. P., Rolfe R. D. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun. 1987 Dec;55(12):2984–2992. doi: 10.1128/iai.55.12.2984-2992.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Leung D. Y., Kelly C. P., Boguniewicz M., Pothoulakis C., LaMont J. T., Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991 Apr;118(4 Pt 1):633–637. doi: 10.1016/s0022-3476(05)83393-1. [DOI] [PubMed] [Google Scholar]
  24. Libby J. M., Jortner B. S., Wilkins T. D. Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun. 1982 May;36(2):822–829. doi: 10.1128/iai.36.2.822-829.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lyerly D. M., Bostwick E. F., Binion S. B., Wilkins T. D. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun. 1991 Jun;59(6):2215–2218. doi: 10.1128/iai.59.6.2215-2218.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lyerly D. M., Saum K. E., MacDonald D. K., Wilkins T. D. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun. 1985 Feb;47(2):349–352. doi: 10.1128/iai.47.2.349-352.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lyerly D. M., Sullivan N. M., Wilkins T. D. Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol. 1983 Jan;17(1):72–78. doi: 10.1128/jcm.17.1.72-78.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. McFarland L. V., Mulligan M. E., Kwok R. Y., Stamm W. E. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989 Jan 26;320(4):204–210. doi: 10.1056/NEJM198901263200402. [DOI] [PubMed] [Google Scholar]
  29. Miller P. D., Pothoulakis C., Baeker T. R., LaMont J. T., Rothstein T. L. Macrophage-dependent stimulation of T cell-depleted spleen cells by Clostridium difficile toxin A and calcium ionophore. Cell Immunol. 1990 Mar;126(1):155–163. doi: 10.1016/0008-8749(90)90308-e. [DOI] [PubMed] [Google Scholar]
  30. Mitchell T. J., Ketley J. M., Haslam S. C., Stephen J., Burdon D. W., Candy D. C., Daniel R. Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. Gut. 1986 Jan;27(1):78–85. doi: 10.1136/gut.27.1.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ogra P. L., Karzon D. T. Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine. J Immunol. 1969 Jun;102(6):1423–1430. [PubMed] [Google Scholar]
  32. Oien N. L., Brideau R. J., Walsh E. E., Wathen M. W. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine. 1994 Jun;12(8):731–735. doi: 10.1016/0264-410x(94)90224-0. [DOI] [PubMed] [Google Scholar]
  33. Pantosti A., Cerquetti M., Viti F., Ortisi G., Mastrantonio P. Immunoblot analysis of serum immunoglobulin G response to surface proteins of Clostridium difficile in patients with antibiotic-associated diarrhea. J Clin Microbiol. 1989 Nov;27(11):2594–2597. doi: 10.1128/jcm.27.11.2594-2597.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Pecquet S. S., Ehrat C., Ernst P. B. Enhancement of mucosal antibody responses to Salmonella typhimurium and the microbial hapten phosphorylcholine in mice with X-linked immunodeficiency by B-cell precursors from the peritoneal cavity. Infect Immun. 1992 Feb;60(2):503–509. doi: 10.1128/iai.60.2.503-509.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Pothoulakis C., Sullivan R., Melnick D. A., Triadafilopoulos G., Gadenne A. S., Meshulam T., LaMont J. T. Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J Clin Invest. 1988 Jun;81(6):1741–1745. doi: 10.1172/JCI113514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Samore M. H., DeGirolami P. C., Tlucko A., Lichtenberg D. A., Melvin Z. A., Karchmer A. W. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis. 1994 Feb;18(2):181–187. doi: 10.1093/clinids/18.2.181. [DOI] [PubMed] [Google Scholar]
  37. Siffert J. C., Baldacini O., Kuhry J. G., Wachsmann D., Benabdelmoumene S., Faradji A., Monteil H., Poindron P. Effects of Clostridium difficile toxin B on human monocytes and macrophages: possible relationship with cytoskeletal rearrangement. Infect Immun. 1993 Mar;61(3):1082–1090. doi: 10.1128/iai.61.3.1082-1090.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Staats H. F., Jackson R. J., Marinaro M., Takahashi I., Kiyono H., McGhee J. R. Mucosal immunity to infection with implications for vaccine development. Curr Opin Immunol. 1994 Aug;6(4):572–583. doi: 10.1016/0952-7915(94)90144-9. [DOI] [PubMed] [Google Scholar]
  39. Takeoka A., Takumi K., Koga T., Kawata T. Purification and characterization of S layer proteins from Clostridium difficile GAI 0714. J Gen Microbiol. 1991 Feb;137(2):261–267. doi: 10.1099/00221287-137-2-261. [DOI] [PubMed] [Google Scholar]
  40. Toma S., Lesiak G., Magus M., Lo H. L., Delmée M. Serotyping of Clostridium difficile. J Clin Microbiol. 1988 Mar;26(3):426–428. doi: 10.1128/jcm.26.3.426-428.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Torres J., Jennische E., Lange S., Lönnroth I. Enterotoxins from Clostridium difficile; diarrhoeogenic potency and morphological effects in the rat intestine. Gut. 1990 Jul;31(7):781–785. doi: 10.1136/gut.31.7.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Viscidi R., Laughon B. E., Yolken R., Bo-Linn P., Moench T., Ryder R. W., Bartlett J. G. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis. 1983 Jul;148(1):93–100. doi: 10.1093/infdis/148.1.93. [DOI] [PubMed] [Google Scholar]
  43. Warny M., Vaerman J. P., Avesani V., Delmée M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun. 1994 Feb;62(2):384–389. doi: 10.1128/iai.62.2.384-389.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wu H. Y., Russell M. W. Comparison of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen given with or coupled to cholera toxin (CT) B subunit, and effects of pre-existing anti-CT immunity. Vaccine. 1994;12(3):215–222. doi: 10.1016/0264-410x(94)90197-x. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES